Abstract

BackgroundLeukotriene B4 (LTB4) has been associated with the initiation and progression of atherosclerosis and abdominal aortic aneurysm (AAA) formation. However, associations of LTB4 levels with tissue characteristics and adverse clinical outcome of advanced atherosclerosis and AAA are scarcely studied. We hypothesized that LTB4 levels are associated with a vulnerable plaque phenotype and adverse clinical outcome. Furthermore, that LTB4 levels are associated with inflammatory AAA and adverse clinical outcome.MethodsAtherosclerotic plaques and AAA specimens were selected from two independent databases for LTB4 measurements. Plaques were isolated during carotid endarterectomy from asymptomatic (n = 58) or symptomatic (n = 317) patients, classified prior to surgery. LTB4 levels were measured without prior lipid extraction and levels were corrected for protein content. LTB4 levels were related to plaque phenotype, baseline patient characteristics and clinical outcome within three years following surgery. Seven non-diseased mammary artery specimens served as controls. AAA specimens were isolated during open repair, classified as elective (n = 189), symptomatic (n = 29) or ruptured (n = 23). LTB4 levels were measured similar to the plaque measurements and were related to tissue characteristics, baseline patient characteristics and clinical outcome. Twenty-six non-diseased aortic specimens served as controls.ResultsLTB4 levels corrected for protein content were not significantly associated with histological characteristics specific for vulnerable plaques or inflammatory AAA as well as clinical presentation. Moreover, it could not predict secondary manifestations independently investigated in both databases. However, LTB4 levels were significantly lower in controls compared to plaque (p = 0.025) or AAA (p = 0.017).ConclusionsLTB4 levels were not associated with a vulnerable plaque phenotype or inflammatory AAA or clinical presentation. This study does not provide supportive evidence for a role of LTB4 in atherosclerotic plaque destabilization or AAA expansion. However, these data should be interpreted with care, since LTB4 measurements were performed without prior lipid extractions.

Highlights

  • Atherosclerosis is a progressive inflammatory disease occurring in the middle and larger arteries that can result in gradual luminal narrowing or acute thrombotic occlusion due to atherosclerotic plaque rupture [1]

  • We investigated the expression of Leukotriene B4 (LTB4) in advanced human atherosclerotic plaques and abdominal aortic aneurysm (AAA) specimens separately in two independent databases

  • We studied the possible link between LTB4 levels and clinical characteristics of patients suffering from atherosclerosis or AAA, separately

Read more

Summary

Introduction

Atherosclerosis is a progressive inflammatory disease occurring in the middle and larger arteries that can result in gradual luminal narrowing or acute thrombotic occlusion due to atherosclerotic plaque rupture [1]. BLT1 is known as the high affinity receptor for LTB4 and is primarily, but not exclusively, expressed by inflammatory cells. The functional relevance of LTB4 and its receptors in atherosclerotic disease have been investigated in mouse models deficient for ApoE or LDLR. Based on these results, specific antagonists for ALOX5 pathway components have been developed to inhibit lesion development. Leukotriene B4 (LTB4) has been associated with the initiation and progression of atherosclerosis and abdominal aortic aneurysm (AAA) formation. Associations of LTB4 levels with tissue characteristics and adverse clinical outcome of advanced atherosclerosis and AAA are scarcely studied. That LTB4 levels are associated with inflammatory AAA and adverse clinical outcome

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call